Rockefeller University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Rockefeller University sits in the top decile of US sponsors by registered trial count (#222 of 15,742 sponsors by registered trial count).

117 total trials 5 currently recruiting 92 completed early-phase tilt top decile by trial count

Rockefeller University: 117 sponsored US clinical trials, 5 recruiting.

Rockefeller University sponsors 117 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 92 completed. 7 of these trials are in Phase 3-4 (later-stage) and 43 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 5 trials.

Top-decile sponsor footprint

Rockefeller University ranks in the top decile of sponsors by registered trial count (#222 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 51/100

92 of 109 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

117 total, page 3 of 3

COMPLETED

Experiments to Test How and Why the Sense of Smell Differs Between People

NCT00220038

COMPLETED Phase 1

Phase I/II, Open-Label Trial of Three Monoclonal Antibodies

NCT00219986

COMPLETED Phase 3

Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis

NCT00115076

COMPLETED Phase 1

Effect of Folate on Colon and Blood Cells

NCT00220012

COMPLETED

Study of the Immune Response to Hepatitis C Virus

NCT00237432

TERMINATED NA

The Effect of Nighttime Dialysis on the Inflammation of Kidney Failure

NCT00234130

COMPLETED Phase 1

Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells.

NCT00289341

COMPLETED

Observational Study of Treated and Untreated Acute and Early HIV-1 Infection

NCT00219934

COMPLETED

Hepatitis C Virus and the Humoral Immune System

NCT00219999

COMPLETED Phase 2

Effects of Leptin Treatment on Weight Loss

NCT00050791

TERMINATED

Viral and Host Factors in the Transmission and Pathogenesis of HIV

NCT00219947

COMPLETED

Study to Evaluate Immune Responses in Neurologically Normal Cancer Patients

NCT00481637

COMPLETED Phase 1

To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris

NCT00050648

COMPLETED Phase 1

To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris

NCT00050661

COMPLETED

The Study of Immune Cell (T Cell) Activity in Patients With Paraneoplastic Neurologic Syndromes

NCT00327236

COMPLETED NA

A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART

NCT00002392

COMPLETED NA

Immunomodulation of HIV-1 Infected Individuals With PEG-Interleukin-2

NCT00002017

← Previous Page 3 of 3

Phase Distribution

PhaseTrial count
Phase 1 37
Phase 2 6
Phase 3 2
Phase 4 5

What is open in the Rockefeller University pipeline

5 recruiting of 117 indexed (4% open); 92 completed (79%).

Phase mix: 7 late (III/IV) vs 43 early (I/II) (early-phase heavy).

Top condition: Obesity (5 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Rockefeller University: open-pipeline peers nationwide

Peers matched on 117 registered trials and 4% open enrollment, not the therapeutic-area sidebar.

Rockefeller University sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400 0%10%20%30%40% Total trials Recruiting share Rockefeller UniversitySan Diego State UniversityChildren's Hospital Los AngelesJaeb Center for Health ResearchMedtronic - MITGCraig L Slingluff, JrEsperion TherapeuticsTonix PharmaceuticalsNational Institute on Drug Abuse (NIDA)
Rockefeller University sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Rockefeller University sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 117 trials (± recruiting share)

Sponsors near 4% open enrollment (± trial volume)

What to do with this Rockefeller University page

117 registered trials is a research-attention snapshot, not an endorsement of Rockefeller University or any single study.

  • 5 of Rockefeller University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition Rockefeller University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Rockefeller University pipeline card: 117 registered trials from official public datasets.Report a data error.